ストックスクリーナーアプリを入手
840.50
0.85%
-7.22
前日終値:
$847.72
開ける：
$849.43
24時間の取引高:
292.61K
Relative Volume:
0.83
時価総額：
$52.01B
収益：
$3.06B
当期純損益:
$1.28B
株価収益率:
42.73
EPS:
19.6719
ネットキャッシュフロー:
$447.35M
1週間 パフォーマンス:
+3.16%
1か月 パフォーマンス:
+0.31%
6か月 パフォーマンス:
+40.34%
1年 パフォーマンス:
+26.26%
1日の値動き範囲:
$832.28
$855.44
1週間の範囲:
$817.02
$881.89
52週間の値動き範囲:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 再開されました | Truist | Buy |
| 2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Insider Monkey
Assessing argenx (ENXTBR:ARGX) Valuation After Recent Share Price Pullback - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Vyvgart Priority Review Puts Argenx Valuation Gap And Pipeline In Focus - Yahoo Finance
Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Finviz
12 Best Healthcare Stocks to Buy for 2026 - Insider Monkey
Argenx’s (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Yahoo Finance
Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317 - Finviz
argenx SE (ARGX): A Bull Case Theory - Finviz
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX) - The Globe and Mail
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Argenx shares rise as FDA reviews Vyvgart for broader use By Investing.com - Investing.com South Africa
Argenx shares rise as FDA reviews Vyvgart for broader use - Investing.com
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - Sahm
William Blair reiterates Outperform rating on argenx stock - Investing.com
Argenx shares slip as Q4 results come in broadly in line By Investing.com - Investing.com South Africa
Argenx shares slip as Q4 results come in broadly in line - Investing.com
Wells Fargo Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
argenx SE stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Argenx stock holds steady as TD Cowen reiterates Buy rating By Investing.com - Investing.com South Africa
Argenx stock holds steady as TD Cowen reiterates Buy rating - Investing.com
Argenx founder Tim Hauwermeiren to step down as CEO; Karen Massey named successor - Investing.com India
argenx Announces Leadership Transition Marking Next Evolution of Growth - Sahm
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Sahm
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Sponsored ADR (ARGX) Stock Price History & Data - Traders Union
BofA Securities raises argenx stock price target to $1,006 on strong Vyvgart outlook - Investing.com India
Baird downgrades argenx stock rating to Neutral on valuation concerns By Investing.com - Investing.com South Africa
Baird downgrades argenx stock rating to Neutral on valuation concerns - Investing.com
Argenx stock price target raised to $925 from $860 at RBC Capital By Investing.com - Investing.com South Africa
Argenx stock price target raised to $925 from $860 at RBC Capital - Investing.com
Argenx stock rating maintained at Buy by BofA despite TED trial failure - Investing.com South Africa
Jefferies maintains Buy rating on argenx stock despite failed TED trial - Investing.com
argenx stock rating reiterated at Buy by Guggenheim despite TED study halt - Investing.com South Africa
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Sahm
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
argenx stock tumbles after discontinuing thyroid eye disease studies - Investing.com
Argenx, Navan And 3 Stocks To Watch Heading Into Monday - Sahm
Immunovant: "Buy" On Competitive Batoclimab Landscape And IMVT-1402 Advancement (IMVT) - Seeking Alpha
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance By Investing.com - Investing.com South Africa
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance - Investing.com India
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth By Investing.com - Investing.com South Africa
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth - Investing.com India
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx NV ADR stock hits all-time high at $934.62 - Investing.com India
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
大文字化:
|
ボリューム (24 時間):